(Q34079590)

30 July 2017

1 reference

title

Neurobehavioral and neuropsychiatric symptoms in Alzheimer's disease: characteristics and treatment (English)

1 reference

30 July 2017

1 reference

Chung JA

1

1 reference

30 July 2017

Cummings JL

series ordinal

2

1 reference

30 July 2017

publication date

1 November 2000

1 reference

30 July 2017

1 reference

30 July 2017

volume

18

1 reference

30 July 2017

issue

4

1 reference

30 July 2017

page(s)

829-846

1 reference

The course of geriatric depression with "reversible dementia": a controlled study

30 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970228-0

7 January 2021

The prevalence, associations and symptoms of depression amongst dementia sufferers.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970228-0

7 January 2021

Efficacy of antipsychotic medications in behaviorally disturbed dementia patients

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970228-0

7 January 2021

Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970228-0

7 January 2021

Clinical features and pharmacologic treatment of behavioral symptoms of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970228-0

7 January 2021

Aggression, suicide, and serotonin: relationships to CSF amine metabolites.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970228-0

7 January 2021

Buspirone vs. Haloperidol: A Double-Blind Trial for Agitation in a Nursing Home Population With Alzheimer's Disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970228-0

7 January 2021

Factors determining the decision to institutionalize dementing individuals: a prospective study.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970228-0

7 January 2021

Assessment of agitation.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970228-0

7 January 2021

Agitated behaviors in the elderly. I. A conceptual review

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970228-0

7 January 2021

The relationship between dementia and elder abuse.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970228-0

7 January 2021

Cerebral blood flow correlates of apathy in Alzheimer disease

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970228-0

7 January 2021

Physostigmine ameliorates the delusions of Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970228-0

7 January 2021

Neuropsychiatric aspects of Alzheimer's disease: the cholinergic hypothesis revisited

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970228-0

7 January 2021

The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970228-0

7 January 2021

The course of psychopathologic features in mild to moderate Alzheimer disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970228-0

7 January 2021

A pilot study of haloperidol treatment of psychosis and behavioral disturbance in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970228-0

7 January 2021

Depressed mood and the incidence of Alzheimer's disease in the elderly living in the community.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970228-0

7 January 2021

Clozapine-related seizures

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970228-0

7 January 2021

Psychotic symptoms and the longitudinal course of senile dementia of the Alzheimer type

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970228-0

7 January 2021

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970228-0

1 reference

7 January 2021

Major depression in a population of demented and nondemented older people: prevalence and correlates.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970228-0

7 January 2021

Neuropathological correlates of psychotic phenomena in confirmed Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970228-0

7 January 2021

Clinical and neuropathological correlates of depression in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970228-0

7 January 2021

Propranolol treatment of assaultive patients with organic brain disease. A double-blind crossover, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970228-0

7 January 2021

Valproic acid treatment of agitation in dementia.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970228-0

7 January 2021

Frontal lobe hypometabolism and depression in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970228-0

7 January 2021

Factors associated with psychotic symptoms in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970228-0

7 January 2021

Risperidone treatment of behavioral disturbances in outpatients with dementia

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970228-0

7 January 2021

The evolution of psychiatric symptoms in Alzheimer's disease: a natural history study

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970228-0

7 January 2021

A double-blind comparison of the efficacy and safely of paroxetine and imipramine in the treatment of depression with dementia.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970228-0

7 January 2021

Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. Risperidone Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970228-0

7 January 2021

Effect of tacrine on behavioral symptoms in Alzheimer's disease: an open-label study

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970228-0

7 January 2021

Efficacy and safety of neuroleptics in behavioral disorders associated with dementia.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970228-0

7 January 2021

Longitudinal assessment of symptoms of depression, agitation, and psychosis in 181 patients with Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970228-0

7 January 2021

Alzheimer disease and frontotemporal dementias. Behavioral distinctions

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970228-0

7 January 2021

Low cerebrospinal fluid 5-hydroxyindoleacetic acid concentration differentiates impulsive from nonimpulsive violent behavior

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970228-0

7 January 2021

Valproate in the treatment of behavioral agitation in elderly patients with dementia.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970228-0

7 January 2021

Major and minor depression in Alzheimer's disease: prevalence and impact

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970228-0

7 January 2021

Physical aggression in dementia patients and its relationship to depression.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970228-0

7 January 2021

Noncognitive disturbances in Alzheimer's disease: frequency, longitudinal course, and relationship to cognitive symptoms.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970228-0

7 January 2021

Operational criteria for senile dementia of Lewy body type (SDLT)

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970228-0

7 January 2021

The spectrum of behavioral changes in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970228-0

7 January 2021

Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970228-0

7 January 2021

Predictors of cognitive and functional progression in patients with probable Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970228-0

7 January 2021

The clinical efficacy of citalopram in treatment of emotional disturbances in dementia disorders. A Nordic multicentre study.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970228-0

7 January 2021

A controlled multicenter clinical study of citalopram and placebo in elderly depressed patients with and without concomitant dementia

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970228-0

7 January 2021

Incontinence and troublesome behaviors predict institutionalization in dementia

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970228-0

7 January 2021

Assessment of behavioral and affective symptoms in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970228-0

7 January 2021

Functional status and cognitive impairment in Alzheimer's patients with and without depression.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970228-0

7 January 2021

An open trial of valproate for agitation in geriatric neuropsychiatric disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970228-0

7 January 2021

Efficacy of risperidone for behavioral disorders in the elderly: a clinical observation

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970228-0

7 January 2021

The effects of metrifonate on the cognitive, behavioral, and functional performance of Alzheimer's disease patients. Metrifonate Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970228-0

7 January 2021

Effect of tacrine on language, praxis, and noncognitive behavioral problems in Alzheimer disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970228-0

7 January 2021

Gabapentin for behavioral agitation in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970228-0

7 January 2021

Dementia of the Alzheimer's type and depression

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970228-0

7 January 2021

Double-blind trial of imipramine in Alzheimer's disease patients with and without depression

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970228-0

7 January 2021

Emergence of psychosis and depression in the longitudinal evaluation of Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970228-0

7 January 2021

A new rating scale for Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970228-0

7 January 2021

Depression and Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970228-0

7 January 2021

A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970228-0

7 January 2021

A metaanalysis of controlled trials of neuroleptic treatment in dementia

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970228-0

7 January 2021

Zolpidem for dementia-related insomnia and nighttime wandering

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970228-0

7 January 2021

A SPECT study of delusions in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970228-0

7 January 2021

Psychiatric symptoms and nursing home placement of patients with Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970228-0

7 January 2021

Predictors of disease course in patients with probable Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970228-0

7 January 2021

The relationship between psychiatric symptoms and regional cortical metabolism in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970228-0

7 January 2021

A double-blind, randomized, fixed-dose trial of fluoxetine vs. amitriptyline in the treatment of major depression complicating Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970228-0

7 January 2021

Efficacy and tolerability of carbamazepine for agitation and aggression in dementia

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970228-0

7 January 2021

Withdrawal from controlled carbamazepine therapy followed by further carbamazepine treatment in patients with dementia

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970228-0

7 January 2021

Fluvoxamine for stereotypic behavior in patients with dementia.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970228-0

7 January 2021

Treatment of depression in advanced Alzheimer's disease using sertraline.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970228-0

7 January 2021

Psychogeriatric dependency rating scales (PGDRS): a method of assessment for use by nurses

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970228-0

7 January 2021

Major depression in primary dementia. Clinical and neuropathologic correlates

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970228-0

7 January 2021

Neurochemical Correlates of Major Depression in Primary Dementia

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970228-0

7 January 2021

Neuropathologic and neurochemical correlates of psychosis in primary dementia.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970228-0

7 January 2021

The neuropathology of aminergic nuclei in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970228-0

7 January 2021

10.1016/S0733-8619(05)70228-0

Identifiers

DOI

1 reference

30 July 2017

1 reference